Abstract: We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said proteins.

Abstract: The invention relates to chimeric recombinant polypeptides, preferably therapeutic polypeptides, for example cytokines or antibodies, which are engineered to include a signal sequence for the attachment of glycosylphosphatidylinositol; cells expressing said polypeptides and methods to manufacture said polypeptides.

Abstract: We describe a chimeric protein comprising a growth hormone polypeptide linked to a polypeptide comprising the extracellular binding domain of growth hormone receptor; its use in enhancing the growth and metabolism of non-human animals and homodimers comprising said chimeric protein.

Abstract: Chimeric polypeptides wherein the polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of such modified growth hormone binding domains.

Abstract: We disclose therapeutic polypeptides comprising at least two domains capable of binding to a cytokine receptor, wherein the domains are connected by a peptide linker, wherein the linker optionally comprises a rigid alpha helical region.

Abstract: The invention relates to chimeric polypeptides wherein said polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of said modified growth hormone binding domains.

Abstract: Agents which bind to cell surface receptors; methods to manufacture such agents; therapeutic compositions comprising such agents; and screening methods to identify novel agents.

Abstract: This invention relates to agents which bind to cell surface receptors; methods to manufacture said agents; therapeutic compositions comprising said agents; and screening methods to identify novel agents.

Abstract: We describe modified cytokine ligand polypeptides comprising a modified amino acid sequence which is a modification of the native cytokine amino acid sequence of said ligand, wherein the native amino terminal and carboxyl terminal amino acid residues of the native polypeptide are linked, directly or indirectly, together, characterised in that said ligand is provided with alternative amino terminal and carboxyl terminal amino acid residues and further wherein at least one binding domain for said ligand's cognate binding partner or receptor complex is disrupted.

Abstract: An exhaust gas cooler assembly (10) with an internally located bypass tube (50), spaced apart from and disposed within a core passage (60), with an exhaust gas inlet manifold (40) directing exhaust gas to a plurality of cooling passages (52, 54, 56, 58) or to the bypass tube (50) by means of control valves (42, 44). Further provided is a detachable valve cartridge (84) with an actuator (16), with all moving components being included within the valve cartridge (84) and actuator (16).

Abstract: An exhaust gas recirculation cooler, typically of the drawn cup design, with a bypass and control valve is disclosed. The control valve can direct a proportion of the exhaust gas to the cooler and a proportion to bypass the cooler depending on the input temperature of the exhaust gas and the required temperature of the exhaust gas. The proportion of the exhaust gas directed to the cooler/bypassing the cooler can be varied as required and so the temperature of the exhaust gas can be controlled. One benefit of certain embodiments of the invention is that engine damaging chemicals, such as sulphuric acid, which result from over-cooling the exhaust gas are reduced.

Abstract: The invention relates to the provision of oligomeric polypeptides (dimers, trimers etc) comprising the ligand binding domains of cytokines which are linked via flexible polypeptide linker molecules. The linker molecules optionally comprise protease sensitive sites to modulate the release of biologically active cytokines when administered to a human or animal subject.

Abstract: The invention relates to chimeric recombinant polypeptides, preferably therapeutic polypeptides, for example cytokines or antibodies, which are engineered to include a signal sequence for the attachment of glycosylphosphatidylinositol; cells expressing said polypeptides and methods to manufacture said polypeptides.

Abstract: An exhaust gas recirculation cooler, typically of the drawn cup design, with a bypass and control valve is disclosed. The control valve can direct a proportion of the exhaust gas to the cooler and a proportion to bypass the cooler depending on the input temperature of the exhaust gas and the required temperature of the exhaust gas. The proportion of the exhaust gas directed to the cooler/bypassing the cooler can be varied as required and so the temperature of the exhaust gas can be controlled. One benefit of certain embodiments of the invention is that engine damaging chemicals, such as sulphuric acid, which result from over-cooling the exhaust gas are reduced.

Abstract: The invention relates to the provision of oligomeric polypeptides (dimers, trimmers, etc) comprising the ligand binding domains of cytokines which are linked via flexible polypeptides linker molecules. The linker molecules optionally comprise protease sensitive sites to modulate the release of biologically active cytokines when administered to a human or animal subject.

Abstract: This invention relates to agents which bind to cell surface receptors; methods to manufacture said agents; therapeutic compositions comprising said agents; and screening methods to identify novel agents.

Abstract: Methods are provided which utilize the endonuclease activity of exonucleases wherein reaction conditions are provided which suppress detectable exonuclease activity but which retain or enhance the endonuclease activity of said exonuclease.

Abstract: A vaccine for eliciting immunity against Schistosoma parasites, comprises a recombinant fusion protein capable of comprising the 27/28 kDa cercarial elastase sequence of S. mansoni or an active fragment, homologue or variant thereof, fused to a suitable bacterial, phage or viral protein, together with a pharmaceutically acceptable excipient or carrier. The vaccine can be used to combat S. mansoni, S. japonicum and/or S. haematobium in mammals, especially humans.